A Phase 2 Study of OBE001 Versus Placebo in the Delay of Preterm Birth
Status:
Terminated
Trial end date:
2017-10-01
Target enrollment:
Participant gender:
Summary
The primary objective of this study is to assess the efficacy of a single dose of OBE001, an
oral oxytocin antagonist, given for up to 7 days to delay preterm birth by 7 days compared to
placebo.